Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer

Silvio Ken Garattini; Marta Bonotto; Luca Porcu; Elena Ongaro; Lorenzo Gerratana; Debora Basile; Annamaria Parnofiello; Giacomo Pelizzari; Francesco Cortiula; Carla Corvaja; Mariaelena Casagrande; Giovanni Gerardo Cardellino; Angela Buonadonna; Giuseppe Aprile; Fabio Puglisi; Gianpiero Fasola; Nicoletta Pella

doi:10.2217/fon-2020-0270

Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer

Silvio Ken Garattini, Marta Bonotto, Luca Porcu, Elena Ongaro, Lorenzo Gerratana, Debora Basile, Annamaria Parnofiello, Giacomo Pelizzari, Francesco Cortiula, Carla Corvaja, Mariaelena Casagrande, Giovanni Gerardo Cardellino, Angela Buonadonna, Giuseppe Aprile, Fabio Puglisi, Gianpiero Fasola, Nicoletta Pella

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Drug holidays' (DH) for metastatic colorectal cancer (mCRC) were introduced to preserve quality of life. We studied factors associated to a DH offer in first line. Materials methods: We retrospectively analyzed 754 consecutive patients treated with chemotherapy for mCRC in two Italian institutions between 2005 and 2017. Associations between baseline clinical-pathological factors and DH (56 or more days of treatment interruption) were investigated. Results: In 754 patients, previous metastasectomy, previous thermoablation and previous surgery of primary tumor were independently associated with DH. Excluding procedures or clinical trials: primary rectal cancer and resection of primary tumor were significantly associated to DH. Conclusions: DH was offered to patients with lower burden of disease, but further investigations are needed to safely guide a holiday strategy.

Original language	English
Pages (from-to)	2645-2660
Number of pages	16
Journal	Future Oncology
Volume	16
Issue number	32
DOIs	https://doi.org/10.2217/fon-2020-0270
Publication status	Published - Nov 2020

Keywords

chemotherapy
colorectal cancer
drug holidays
metastasis

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2020-0270

Fingerprint Dive into the research topics of 'Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this

Garattini, S. K., Bonotto, M., Porcu, L., Ongaro, E., Gerratana, L., Basile, D., Parnofiello, A., Pelizzari, G., Cortiula, F., Corvaja, C., Casagrande, M., Cardellino, G. G., Buonadonna, A., Aprile, G., Puglisi, F., Fasola, G., & Pella, N. (2020). Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. Future Oncology, 16(32), 2645-2660. https://doi.org/10.2217/fon-2020-0270

Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. / Garattini, Silvio Ken; Bonotto, Marta; Porcu, Luca; Ongaro, Elena ; Gerratana, Lorenzo; Basile, Debora; Parnofiello, Annamaria; Pelizzari, Giacomo; Cortiula, Francesco; Corvaja, Carla; Casagrande, Mariaelena; Cardellino, Giovanni Gerardo; Buonadonna, Angela; Aprile, Giuseppe; Puglisi, Fabio; Fasola, Gianpiero; Pella, Nicoletta.

In: Future Oncology, Vol. 16, No. 32, 11.2020, p. 2645-2660.

Research output: Contribution to journal › Article › peer-review

Garattini, SK, Bonotto, M, Porcu, L, Ongaro, E , Gerratana, L, Basile, D, Parnofiello, A, Pelizzari, G, Cortiula, F, Corvaja, C, Casagrande, M, Cardellino, GG, Buonadonna, A, Aprile, G, Puglisi, F, Fasola, G & Pella, N 2020, 'Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer', Future Oncology, vol. 16, no. 32, pp. 2645-2660. https://doi.org/10.2217/fon-2020-0270

Garattini, Silvio Ken ; Bonotto, Marta ; Porcu, Luca ; Ongaro, Elena ; Gerratana, Lorenzo ; Basile, Debora ; Parnofiello, Annamaria ; Pelizzari, Giacomo ; Cortiula, Francesco ; Corvaja, Carla ; Casagrande, Mariaelena ; Cardellino, Giovanni Gerardo ; Buonadonna, Angela ; Aprile, Giuseppe ; Puglisi, Fabio ; Fasola, Gianpiero ; Pella, Nicoletta. / Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. In: Future Oncology. 2020 ; Vol. 16, No. 32. pp. 2645-2660.

@article{6e3eef77d3d54b8bb11c6425f42b6012,

title = "Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer",

abstract = "Background: Drug holidays' (DH) for metastatic colorectal cancer (mCRC) were introduced to preserve quality of life. We studied factors associated to a DH offer in first line. Materials methods: We retrospectively analyzed 754 consecutive patients treated with chemotherapy for mCRC in two Italian institutions between 2005 and 2017. Associations between baseline clinical-pathological factors and DH (56 or more days of treatment interruption) were investigated. Results: In 754 patients, previous metastasectomy, previous thermoablation and previous surgery of primary tumor were independently associated with DH. Excluding procedures or clinical trials: primary rectal cancer and resection of primary tumor were significantly associated to DH. Conclusions: DH was offered to patients with lower burden of disease, but further investigations are needed to safely guide a holiday strategy.",

keywords = "chemotherapy, colorectal cancer, drug holidays, metastasis",

author = "Garattini, {Silvio Ken} and Marta Bonotto and Luca Porcu and Elena Ongaro and Lorenzo Gerratana and Debora Basile and Annamaria Parnofiello and Giacomo Pelizzari and Francesco Cortiula and Carla Corvaja and Mariaelena Casagrande and Cardellino, {Giovanni Gerardo} and Angela Buonadonna and Giuseppe Aprile and Fabio Puglisi and Gianpiero Fasola and Nicoletta Pella",

year = "2020",

month = nov,

doi = "10.2217/fon-2020-0270",

language = "English",

volume = "16",

pages = "2645--2660",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "32",

}

TY - JOUR

T1 - Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer

AU - Garattini, Silvio Ken

AU - Bonotto, Marta

AU - Porcu, Luca

AU - Ongaro, Elena

AU - Gerratana, Lorenzo

AU - Basile, Debora

AU - Parnofiello, Annamaria

AU - Pelizzari, Giacomo

AU - Cortiula, Francesco

AU - Corvaja, Carla

AU - Casagrande, Mariaelena

AU - Cardellino, Giovanni Gerardo

AU - Buonadonna, Angela

AU - Aprile, Giuseppe

AU - Puglisi, Fabio

AU - Fasola, Gianpiero

AU - Pella, Nicoletta

PY - 2020/11

Y1 - 2020/11

N2 - Background: Drug holidays' (DH) for metastatic colorectal cancer (mCRC) were introduced to preserve quality of life. We studied factors associated to a DH offer in first line. Materials methods: We retrospectively analyzed 754 consecutive patients treated with chemotherapy for mCRC in two Italian institutions between 2005 and 2017. Associations between baseline clinical-pathological factors and DH (56 or more days of treatment interruption) were investigated. Results: In 754 patients, previous metastasectomy, previous thermoablation and previous surgery of primary tumor were independently associated with DH. Excluding procedures or clinical trials: primary rectal cancer and resection of primary tumor were significantly associated to DH. Conclusions: DH was offered to patients with lower burden of disease, but further investigations are needed to safely guide a holiday strategy.

AB - Background: Drug holidays' (DH) for metastatic colorectal cancer (mCRC) were introduced to preserve quality of life. We studied factors associated to a DH offer in first line. Materials methods: We retrospectively analyzed 754 consecutive patients treated with chemotherapy for mCRC in two Italian institutions between 2005 and 2017. Associations between baseline clinical-pathological factors and DH (56 or more days of treatment interruption) were investigated. Results: In 754 patients, previous metastasectomy, previous thermoablation and previous surgery of primary tumor were independently associated with DH. Excluding procedures or clinical trials: primary rectal cancer and resection of primary tumor were significantly associated to DH. Conclusions: DH was offered to patients with lower burden of disease, but further investigations are needed to safely guide a holiday strategy.

KW - chemotherapy

KW - colorectal cancer

KW - drug holidays

KW - metastasis

UR - http://www.scopus.com/inward/record.url?scp=85097582091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097582091&partnerID=8YFLogxK

U2 - 10.2217/fon-2020-0270

DO - 10.2217/fon-2020-0270

M3 - Article

C2 - 32776795

AN - SCOPUS:85097582091

VL - 16

SP - 2645

EP - 2660

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 32

ER -